Please assess the completion status of the following clinical trial:

Trial Title: Ketamine in the Treatment of Suicidal Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Unipolar depression with current major depressive episode (MDE). Participants may be psychiatric medication-free, or if on psychiatric medication, not responding adequately given current MDE with suicidal ideation (See 2).~* Moderate to severe suicidal ideation~* 18-65 years old~* Participants must agree to a voluntary admission to an inpatient research unit at the New York State Psychiatric Institute (NYSPI)for the infusion(s), for a brief stay, or longer if clinically necessary.~* Pre-menopausal female participants of child-bearing potential must be willing to use an acceptable form of birth control during study participation such as condoms, diaphragm, or oral contraceptive pills.~* Able to provide informed consent~* Participants 61-65 years old must score a 25 or higher on the Mini-Mental State Examination (MMSE) at screening.~EXCLUSION CRITERIA:~* Unstable medical condition or neurological illness, including baseline hypertension (BP\>140/90) or significant history of cardiovascular illness.~* Significant ECG abnormality~* Pregnant or lactating~* Diagnosis of bipolar disorder or psychotic disorder~* Contraindication to any study treatment.~* Inadequate understanding of English.~* Prior ineffective trial of or adverse reaction to Ketamine or Midazolam.~* Opiate use greater than total daily dose of 20mg Oxycodone or equivalent during the 3 days pre-infusion.~* A diagnosis of sleep apnea.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: ACTIVE_COMPARATOR): 0.02 mg/kg, I.V. (in the vein)
- Ketamine (Type: ACTIVE_COMPARATOR): 0.5 mg/kg, I.V. (in the vein)

Based on this trial design, predict the completion outcome and termination type (if applicable).